Company intelligence / Profile preview

Triastek

Ownership: Private
Employees: ~200
Development stage: Phase 2

Overview

Triastek has established itself as a global leader in the application of proprietary pharmaceutical-grade additive manufacturing. Its lead programs leverage the MED® platform for precise control over drug release profiles and targeted delivery. The company has completed more than ten human data validations and received FDA IND clearance for its gastric retention product T20G. Its T21 program for ulcerative colitis has successfully completed first-in-human trials.

Therapeutic areas: OtherRheumatologyGastroenterologyCardiovascularNephrology
Modalities: Small molecules (oral solid dosage forms)Oral biologics/peptidesRNA therapeutics (in collaboration with BioNTech)
Industry: Biotech

Drug pipeline

5 assets

D23A

4 more assets in the full pipeline.

Partnerships

Eli LillyMerck KGaABoehringer IngelheimSiemensSperogenixBioNTech SE [for oral RNA therapeutics].

Beyond the preview

Go deeper on Triastek.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Triastek.